Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8 + T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. The gene discussed is CD8A; the disease is neoplasm.